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ACUTE EFFECTS OF PHENYTOIN AND THIORIDAZINE, ALONE AND IN
COMBINATION, UPON WATER INTAKE AND BODY
WEIGHT CHANGES IN RATS
Miriana Witzig-Krstic^ M.A.
Western Michigan University, 1984
Concommitant medication of anticonvulsants and psycho
tropics appears to be predominant among mentally retarded,
geriatric, and psychiatric in- and out-patient populations.
Despite suggested interaction and toxicity resulting from
such combination treatment, substantial data remains una
vailable.

This study was designed to explore effects of

dual treatment of thioridazine <TRZ) and diphenylhydantoin
(DPH), two of the drugs most commonly received by the above
mentioned populations.

Seventy-two male Sprague-Dawley rata

were used as subjects whereby the effects of varying doses
of phenytoin (0.0, 4.0 and 8.0 mg/kg) and thioridazine <0.0,
5.0, 10.0 and 20.0 mg/kg), alone and in combination, upon
water intake and body weight as the dependent variables,
were measured and evaluated.

Comparisons of body weight

changes via two-way AN0VA procedures demonstrated signifi
cant differences 24 hours after treatment, showing clear
interaction effects between the two drugs.

Furthermore,

when relative water intakes were compared, a main effect of
thioridazine emerged during the first 24 hours post-treatnent.

The findings support the suggestion that interactions

can occur as the result of concommitant use of these two
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drugs.

Thus, careful evaluation and rather conservative

approval of concommitant use of the agents In question Is
Indicated.
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CHAPTER I
INTRODUCTION
Because psychotropic medications are frequently given
in combinations, often for extended periods, the difficul
ties inherent in the control of drug-induced behavioral
side-effects are compounded.

Increasingly, antipaychotic-

and anticonvulsant combinations (especially phenothiazines
and diphenylhydantoin (DPH)) are being given on both in
patient and out-patient bases.

However, the potential

untoward effects of these combinations are often either
unknown or only anecdotally described.
Without exception, all drugs exert multiple effects.
Drugs given for behavioral effect (e.g. paychotropics, anti
convulsants) may often yield therapeutically relevant
'main effects,' but may also yield numerous therapeutically
troublesome 'side effects'

(Julien, 1980).

Notorious in

this regard have been the phenothiazine antipsychotics (e.g.
chloropromszine (Thorazine); thioridazine (TRZ, Mellaril))
(Ferguson and Breuning, 1982; Fischman, Smith, and Schuster,
1976; Baldwin and Peters, 1968; Anders and Ciaronello, 1977;
Souvner and Harley, 1972), as well as the hydantoin anticon
vulsants (diphenylhydantoin (DPH, Dilantin))

(Hereafter,

diphenylhydantoin and thioridazine will be abbreviated as

1
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DPH and TR2) (Pippenger, 1981; Gibbs, Gibbs, Gibbs, Gibbs,
Dikmen, and Herman, 1982).

Numerous drug-induced disorders

have been reported for these agents including: (1) motor
dysfunctions (e.g. tardive dyskinesia. Parkinsonian-like
symptoms),

(Baldesorini, 1980)

(2) decreased learning

abilities (Wysocki, Fuqua, Davis, and Breuning, 1981), and
(3) marked changes in the sensorium,

alterations in the EEG

recordings and other indices of neurological dysfunction
(Iivanainen and Viukari, 1977; Shagass and Straumanis,
1978).

Even though both phenothiazines and hydantoin anti

convulsants have been in clinical use for decades, their
full range of side-effects is still incompletely understood
and documented

(Hasten, 1970; Hicks, Funkenstein, Dysken,

and Davis, 1980; Shader and Dimascio, 1970).

Ethical

pharmacological treatment requires that these side effects
be anticipated and controlled as much as is technically
possible.
Mentally Retarded Population

An estimated 55X of institutionalized mentally retarded
individuals as well as those in foster homes receive various
combinations of antipsychotic and anticonvulsant drugs, 60*
of which involve TRZ administrations (Breuning, Ferguson,
Davidson, and Poling, 1983).

In mentally retarded popula

tions, the incidence of these two-drug combinatory treat
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ments ia particularly prevalent, in part because the men
tally retarded are more seizure-prone than the population in
general and the psychiatric populations as well (Bosches and
Gibbs, 1972); therefore, they are prescribed anticonvulsants
more frequently (Robinson and Robinson, 1976).

In addition,

the mentally retarded are often chronically treated with
high dosea of the phenothiazines (Lipman, 1970) to gain
greater control over various assaultive, non-compliant,
and/or disruptive behaviors exhibited in ward settings
(Zimmerman and Heistad, 1982; Goldberg and Kurlien, 1970;
Linnoila, Viukari, Vaisanen, and Auvinen, 1980).

Geriatric Population

Patients over age 65 comprise 10* of the tdtal popula
tion in the United States; however, the same group receives
22* of all prescription medicine (Cheung and Vlaases, 1980).
It has been noted that persons over 65 years of age comprise
21* of all first admissions to state or community mental
hospitals (Clark and Delguidice, 1970).

An average nursing

home patient, for example, may receive up to sixteen dif
ferent medications concommitantly (Cheung and Vlasses, 1980).
Naturally, the more drugs a patient receives, the higher the
probability will be of experiencing multiple adverse drug
interactions.
sumption.

Two nursing home studies reinforce this as

As Cheung and Vlasses stated, "In one study, 49*
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of the patients had the potential for at least one drug
interaction; in another study of seven nursing homes, 124
out of 130 patients exhibited potential interaction" (Cheung
and Vlasses, 1980).
There appears to exist an increasing reliance on
combination treatments of phenothiazines and DPH within the
geriatric population.

Geriatric patients are prone to

severe physical illnesses such as cardiac and respiratory
disorders, arteriosclerosis, and stroke--all potentially
resulting in cerebral anoxia.

These diseases manifest them

selves in symptoms such as mental confusion, disorientation
of time and space, lack of attention and concentration,
memory loss, irritability, restlessness, anxiety, and
depression (Daniel, 1970; Shader and Greenblatt, 1982;
Greer, 1982).

Patients exhibiting these symptoms are

commonly treated with various antipsychotic drugs, TRZ being
the one most frequently administered (Clark and Delguidice,
1970).

The geriatric population is more likely to suffer

from several diseases such as cerebral tumours, organic
brain disorders, metastatic tumours, and sedative-hypnotic
abuse (Solomon and Patch, 1974; Sloan, 1983; Bosches and
Gibbs, 1972; Sutherland, Tait, and Eadie, 1974; Simon,
1980), all of which can cause seizures and for which anti
convulsant drugs are administered.
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Psychiatric Population

Institutionalized psychiatric patients often are
treated with the TRZ-DPH combination.

It is widely held,

especially among neurologists, that persons suffering from
seizure disorder (especially temporal lobe seizures) exhibit
various personality and behavioral disorders (Geschwind,
Shader, Bear, North, Levin, and Chetham, 1980; Schmidt and
Wilder, 1968; Solomon and Patch, 1974).

Gibbs and Gibbs

found that 50« of temporal lobe seizure-prone patients suf
fer from some type of psychiatric disorder
Gibbs, 1968; Glaser, 1964).

(Gibbs and

Moreover, for the purpose of

reducing irritability, and aggressive behavior among non
epileptic chronic psychiatric patients, Pinto, Simopoulos,
McGee, Ulenhuth, and DeRosa (1974) have suggested that the
combination treatment of DPH and phenothiazine is useful.
This suggestion was reinforced by Bach-y-Rita, Lyon, and
Clement (1971), who found this combination useful in
treating 136 patients with assaultive and destructive beha
vior.

(Pinto, Simopoulos, McGee, Ulenhuth, and DeRosa, 1974;

Bach-y-Rita, Lyon, and Clement, 1971).
The possibility of drug interaction must be taken
into account when drugs are used concommitantly. Inter
actions can occur at many levels including absorption, dis
tribution, biotransformation, and elimination (Klassen,
1980; Goth, 1978; Hussar, 1980).

For an example involving
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drug distribution processes, drug displacement from bloodprotein drug-binding sites may cause unusually large freedrug concentrations in plasma, which can produce toxic side
effects (Goth,' 1978; Hussar, 1980; Hicks, et. al. , 1980).
For another example, DPH metabolism can significantly change
when other drugs are concommitantly administered (Woodbury,
Penry, and Schmidt, 1972; Eadie and Tyrer, 1974; Hussar,
1980).

Interaction-induced inhibition of DPH metabolism is

common and can create elevated DPH plasma levels eventuating
toxicological responses
1974).

(Huaaar, 1980; Eadie and Tyrer,

In two cases of receiving TRZ and DPH concurrently,

patients exhibited drug intoxication which was due to
altered drug metabolism which had in turn caused elevated
DPH plasma levels.

The toxicity observed in these patients

resulted in behavioral aberrations such as ataxia (diffi
culty of muscle coordination), nystagmus (involuntary move
ment of the eyes), inability to concentrate, and lethargy
(Vincent, 1980).
The present study was conducted in an attempt to ex
plore acute influences of various dose combinations of DPH
and TRZ, as well as to test the hypothesis that mammals
receiving this two-drug combinatory treatment may be at high
risk of developing adverse drug-drug interaction.

Rodent

water intake and associated body weight changes were used as
dependent measures for several reasons.

First, many drugs

are administered on the basis of milligrams of drug per
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kilogram of body weight (Goth, 1978), thus a drastic change
in body weight as the result of an adverse reaction to a
pharmacological agent might lead to serious complications,
especially when administration of such a drug continues
without readjustment of the dosage

(Raman and Smith, 1968).

Furthermore, numerous studies have shown that alterations in
body weight are indications of adverse effects of pharmaco
logical agents

(Kesselring, Sewell, Gallus, Stiger, and Near-

chou, 1983; Sewell, Gallus, and Nanry, 1982).

Also, drugs that

have cholinergic effects (e.g. TRZ) are known to influence
water intake

(Seiden and Dykstra, 1977).

The alteration of

water intake can lead to serious behavioral and physiological
complications, especially when such drugs are not clinically
expected to create such effects

(Sandifer, 1983; Raskid, Ore-

stein, and Graham, 1975).
Male Sprague-Dawley rats were chosen as subjects for
the experiment for several reasons.

First, since research

is largely absent pertaining to potential adverse DPH-TRZ
interactions, important ethical complications taint the use
of experimental treatments to deliberately provoke adverse
reactions in humans.

Second, the physiological organization

of these animals is similar to humans; therefore it is
expected that they might exhibit many similar behavioral,
The use of rodents also provides various other advantages.
Subject characteristics such as age, sex, weight, drug his
tory, and nutrition can be controlled.

Problems created by
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existing pathologies (e.g. seizures, organic brain dys
function, psychosis) can be eliminated.
variables common to humans

Other confounding

(e.g. changes in food and water

intake, social interactions, and temperature)
eliminated.

can also be

(Steinberg, Reuck, and Knight, 1964).

Using

male Sprague-Dawley rats is also practical for reduction of
experiment costs,

number of personnel needed, and

the

amount of time necessary to properly conduct the study.
Male Sprague-Dawley rats were chosen over females since they
exhibit fewer hormonal influences which could have altered
drug response.
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CHAPTER II
METHOD

Subjects

Seventy-two male Sprague-Dawley rata
mately 485 + 47 gn>. <x

weighing approxi

S.D.), and bred and raiaed in the

animal colony of the Laboratory in Behavioral Effects of
Cancer Therapy, served aa subjects.

Subjects were indi

vidually housed under constant temperature (ca. 23 degrees
C> and an alternating day/night cycle <12 hr: 12 hr).
Purina Laboratory Rat Chow (Rat Chow 5012, Ralston Purina
Co., St. Louis, MO) and water were continuously available
for all subjects.

Apparatus

Water Intake monitors

Water intake was measured via modified 100-ml
graduated cylinders functioning as fluid reservoirs (Corning
Glass).

These reservoirs were filled with water, inverted,

and subsequently attached to individual, stainless steel
cages (32 x 24 x 20 cm; Unifab Corp., Kalamazoo, MI).

9

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Jota! body weights

Individual body weights were determined daily with a
mechanical top-loading scale (Pelouze, Model 1000).

Procedure

Water Intake and body measurements

Water intake was monitored by noting net changes in
milliliters absent from fluid reservoirs over five consecu
tive 24-hour periods.

At the end of each 24-hour period,

reservoirs were emptied and then refilled with fresh water.
A two-day baseline period occurred, during which daily body
weight and water intake assessments were performed. At the
beginning of Observation Day 3, each subject received two
intrafJeritoneal (IP) injections, one being DPH, the other
TRZ.

There then ensued three 24-hour periods of water

intake and associated weight change monitoring.

A total of

six subjects per group was assigned to each treatment combi
nation via random selection procedures.

With three dose

levels of DPH and four of TRZ, a total of twelve treatment
groups were thus formed.
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Drug Preparation and Administration

Diphenylhydantoin (phenytoin, Dilantin,

(TM Parke-

Davis), DPH) was dissolved in a vehicle containing 40%
propylene glycol, 10% alcohol in water, and 50% distilled
water and adjusted to pH=12 with sodium hydroxide.
delivered IP at volumes of 4 ml/kg.
explored were 0, 4, and 8 mg/kg.

It was

Those doses of DPH

These doses were selected

by reference to previous phenytoin studies employing rodents
(Schechter and Greer, 1983; Rizzo, Morselli, and Garratani,
1972; Kraft, Lyon, and Poling, 1982) and observations
conducted prior to the interaction study.
At the time of DPH administration, a second IP injec
tion containing the antipsychotic thioridazine, was also
given.

Thioridazine (Mellaril, (TM Sandoz), TRZ) was pre

pared by dilution into physiological saline and injected IP
at a volume of 1.0 ml/kg.

TRZ effects were examined over

the dose range 0, 5, 10, and 20 mg/kg.

TRZ dose levels were

selected by reference to previous research (Halperin and
Guerin, 1983) and initial observations.

Presented in Table

1 are all DPH-TRZ dose combinations which were employed.
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TABLE 1

All phenytoin-thioridazine combinations employed in the
interaction study.
second.

In each cell, P is present first with T

Each treatment combination was given to an

N=6/group.

D
P
H

0,0

4,0

8,0

O
In

TRZ dose (mg/kg)
(T)

0,10

0,20

4,5

4,10

4,20

8,5

8,10

8,20

<P>
D
0
S
E

(mg/kg)

Statistical Analysis

The main statistical assessments consisted of two-way
analyses of variance (Two-way ANOVAs), where one factor was
dose of thioridazine and the second factor was dose of
phenytoin, and for which both main and interactive effects
were evaluated.

Subsequent to each over-all two-way ANOVA
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(I.e. for body weights, for absolute water intakes and for
relative water intakes for each day in question), Duncan's
Multiple Range Teats (i.e. Duncan's) were performed.

Dun

can's tests were executed if: a) an overall two-way ANOVA
demonstrated significance and b) if interactive effects were
absent.

All statistical analyses used significance levels

of alpha = 0.05, and all were performed via use of the SAS
software package installed on The Upjohn Company (Kalamazoo,
Michigan) IBM computer system.

Except for baseline absolute

body weight examined for homogeneity across groups on Day 3
of study, all data were transformed into difference (or
"change") scores such that for all three dependent
variables, baseline values were subtracted from succeeding
days' data.

With difference scores thus obtained, two-way

ANOVAs and ensuing Duncan's were then executed.
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CHAPTER III

RESULTS
Absolute Water Intake Effects

After baseline variabilities were factored out by sub
tracting

Day 2 absolute water intakes from Day 3 water

intakes, these difference scores were analyzed via two-way
ANOVA procedures.

A main effect, a decrease in water in

take, of TRZ dose was established, yet both a main effect of
DPH dose and an interaction effect were found lacking CDoseT: F=3.90, df=3, p<0.0130; Dose-P: F=1.89, df=2, p<0.1596;
Interaction: F=1.8S, df=2, p<0.0989).

Difference scores

obtained by contrasting Day 2 and Day 4 absolute intake
values were examined via two-way ANOVA techniques and no
significant main or interactive effects were found
F=1.56, df=3, p<0.2081; Dose-P:
Interaction:

(Dose-T:

F=3.10, df=2, p<0.0526;

F=0.1527, df=6, p<0.1527).

When difference

scores were obtained by subtracting Day 2 from Day 5 and
these differences were then subjected to two-way ANOVA pro
cedures, no significant group differences were found
T: F=0.12, df=3, p<0.9437; Dose-P:
Interaction:

(Dose-

F=0.97, df=2, p<0.3867;

F=1.03, df=6, p<0.4134). Duncan's tests were

employed only when interactive effects were not uncovered,
yet main effects were found, in the two-way analyses of

14
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absolute water intake.

When TR2 was analyzed in isolation,

0 mg/kg was found to be significantly different from 10 and
20 mg/kg but not different from 5 mg/kg.

Furthermore, the

10 and 20 mg/kg dose levels did not differ significantly in
their effects from each other, nor did the 5 and 20 mg/kg
levels differ from one another.

Due to a lack

of over-all

two-way AN0VA effects for Day 4 and Day 5, Duncan's tests
were not executed for these later data.

Duncan's test

results performed for DPH in isolation revealed no signifi
cant differences across DPH dose.
In summary, when absolute water intake differences were
explored via two-way AN0VA procedures, only a main effect
(decrease in H 2 O intake) of TRZ dose on Day 3 of the study
emerged.

All other main and interactive effect possibili

ties for this dependent variable were absent.

Relative Water Intake Effects

When relative water intakes on Day 2 were subtracted from
those on Day 3 of study, and these difference scores were
then analyzed, via two-way AN0VA procedures, a main effect
of TRZ emerged, but a main effect of DPH as well as an
interaction effect of the two drugs remained lacking

(Dose-

T: F=3.58, df=3, p<0.0188; Dose-P: F=2.05, df=2, p<0.1371;
Interaction: F=1.61, df=6, p<0.1609). When analyzed via twoway AN0VA procedures difference scores calculated from Day 2
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to Day 4 and then again from Day 2 to Day 5

in relative

water intakes revealed no significant main or interactive
effects

(DR4=

Dose-T: F=1.43, df=3, p<0.2424; Dose-P:

F=2.48, df=2, p<0.0919>

<DR5=

Dose-T: F=0.16, df =3,

p<0.9192; Dose-P: F=0.76, df=2, p<0.4719; Interaction:
F=0.97, df=6, p<0.4527) Similar to the analysis of absolute
water intake changes, Duncan's tests were executed when only
interactive effects were discovered in two-way ANOVAs.

As

no overall main effects were revealed for Day 4 and Day 5,
Duncan's tests were not employed.

Overall main effects were

revealed in the two-way ANOVA of Day 3, however; Duncan's
analysis of thioridazine-in-isolation demonstrated that the
0 mg/kg dose level differed significantly from the 5, 10,
and 20 mg/kg dose levels, yet, neither the 0 and 5 mg/kg
effects nor the 5, 10, and 20 mg/kg effects differed from
the other.
In summary, as with absolute water intake, when rela
tive water intake differences were analyzed via two-way
ANOVA procedures, only a main effect of TRZ dose on
Day 3 of study was found.

All other main and interactive

effect possibilities for this dependent variable were
lacking.

Body Weight Effects

Pre-drug total body weights were analyzed by the two-
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way ANOVA model procedure (I.e., those weights taken imme
diately before drug administration).

No significant weight

effects due to random selection factors were found prior to
drug administration
P:

(Dose-T:

F=0.54, df =3, p<0.6611; Doae-

F=0.10, df =2, p<0.9023; Interaction: F=0.09, df=0.09,

p<0.9972).

In other words, body weight means could not be

considered significantly different prior to drug treatment.
When the differences taken between Day 3 and Day 4 body
weights (i.e., weight taken 24 hours after drug treatment)
were analyzed via two-way ANOVA procedures, clear interac
tion effects were found between and TRZ and DPH (Dose-T:
F=3.55, df=3, p<0.0194; Dose-P: F=13.50, df=2, p<0.0001;
Interaction: F=2.27, df=6, p<0.0486).

When differences were

taken between Day 3 and Day 5 body weights, and two-way
ANOVA procedures then performed, no interaction effect was
found, yet main effects of both TRZ and DPH doses remained
(Dose-T: F=5.17, df=3, p<0.0031; Dose-P: F=5.37, df=2,
p<0.0071; Interaction: F=0.7850, df=6, p<0.53).

Where sig

nificant interaction effects were not found, Duncan's tests
were used.
5.

As such, Duncan's test was employed only for Day

When TRZ dose was examined in isolation, 0 mg/kg was

found to differ significantly from 5 and 20 mg/kg, but not
10 mg/kg.

When DPH dose was analyzed in isolation, 8 mg/kg

was found to significantly differ from 4 mg/kg treatment
effects.
In summary, then, a time-course of TRZ-DPH interaction
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emerged in which weight interaction effects were apparent 24
hours after administration but not at 48 hours post
treatment.

Though interaction effects had disappeared by 48

hours, main TRZ and DPH influences on body weight remained.

Figures

Presented in Figure 1 are the results of TRZ-DPH
treatments upon absolute water intake across the five days
study.

of

Drug treatments ocurred on Day 3, prior to the 24-

hour water intake observation period.
Figure 2 presents DPH-TRZ effects upon relative water
intake, across the five days of observation.

Drugs were

administered on Day 3, immediately before the 24-hour
observation period occurred.
Figure 3 presents the influence of DPH-TRZ treatments
upon body weight, across the five days of observation.
Weights were taken on Day 3 and drugs were then admin
istered, thus the first influence of treatment is not ob
served until Day 4.

Figure 4 presents all post-administra

tion data, expressed as "change" or "difference" scores from
respective baseline values.

Body weight, absolute intake,

and relative water intake difference scores are all plotted
as functions of TRZ dose, under respective DPH dose condi
tions.

Plots are provided for both the first and second 24-

hour periods following drug treatments.

Each data point
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point represents the mean performance and standard error for
groups of six subjects each.
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Figure 1.

Rates of water consumption among the 12 treatments.
N=6/treatment group. Dosages are in mg/kg body
weight of phenytoin <P) and thioridazine <T).
Drugs administered intraperitoneally on Day 3.
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Relative rates of water consumption (ml/gr body
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Drugs administered intraperitoneally on Day 3.
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Body weights among the 12 treatment groups.
N®6/treatment group. Dosages are in mg/kg body
weight of phenytoin <P> and thioridazine (P>.
Drugs administered intraperitoneally on Day 3.
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CHAPTER IV
DISCUSSION

In the introduction, several reasons for vigilant moni
toring of body weight changes and water intake were men
tioned.

Such changes are sometimes induced by specific

drugs or as a result of drug-drug interaction.

The results

obtained in this study address several specific issues
regarding changes induced by concommitant DPH-TRZ admini
stration.

As displayed in Figure 4 changes in body weight,

absolute water intake, and relative water intake were found.
The hypothesis that concommitant DPH-TRZ administration
results in changes in body weight was also supported by the
present results.

In Figures 4, Graphs 1 and 2 show the

general trend of decreased body weight, especially during
the 24-hour period following drug administration.

However,

Graph 3 shows that when a higher dose of DPH is administered
<P=8mg/kg), this trend no longer exists; moreover, a slight
increase in body weight emerges.

The exact mechanism of

action leading to this condition is not yet known.

That TRZ

and DPH do interact is important, however, since such condi
tions can lead to serious complications influencing physio
logical and behavioral function.
A clinical case study referring to drug toxicity due to
concommitant administration of DPH and TRZ was cited ear-

24
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liar.

In this instance, while receiving TRZ and DPH concur

rently, two patients exhibited drug intoxication which was
due to altered drug metabolism which caused elevated DPH
plasma levels.'

The toxicity observed in these two patients

resulted in behavioral aberrations such as ataxia, nystag
mus, inability to concentrate, and lethargy (Vincent,
I960).

Furthermore, animal studies suggest that when DPH is

given concommitantly with certain other drugs, pharmacological effects of DPH may be increased by drug-induced inhibi
tion of hepatic metabolism, leading to elevation of DPH
plasma levels and eventual toxicity
1972).

(Kutt and McDowall,

A study of serum concentrations of anticonvulsant

drugs (Reynolds and Travers, 1976) has indicated that toxic
doses of DPH (with dose directly related to plasma concen
tration) may precipitate an acute or subacute cerebral syn
drome often labeled as "psychosis," "confused state," "delerium," or "encephalopathy"
Vaillancourt, 1970).

(Demers-Derosiers, Nestoros, and

Yet often these symptoms are misdiag

nosed as symptoms of idiopathic psychiatric disturbance since
the classic signs of DPH intoxication
mus) may not be evident

(i.e. ataxia, nystag

(Reynolds and Travers, 1976).

Furthermore, when both relative and absolute H2 O intake
changes were examined for the first 24-hours post-drug, a
statistically significant main effect of TRZ emerged.

The

data shown in Figures 1, 2, and 4 demonstrate that TRZ
administration caused a significant decrease in water in
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take.

The physiological mechanism of such a decrease re

mains unclear.

However, there are several possible mecha

nisms that may explain the obtained results.

First, because

of anticholinergic and antiadrenergic properties of TRZ,
atropine-like effects should be expected

(Goth, 1975).

Studies with rats demonstrate that water intake can be
blocked by either topical or systemic treatment with atro
pine

(Grossman, 1969). In addition, research indicates that

haloperidol, another antidopaminergic antipsychotic, pro
duces a marked decrease in water Intake when injected into
the lateral hypotalasmua or septal areas.

This action is

accredited to the drug's effect on the dopaminergic pathways
(Raskid, Orestein, and Graham, 1975).

Because TRZ exhibits

similar dopaminergic-blocking action, it is plausible that
similar action under TRZ might have taken place in the
present study.

Mechanism of action of antipsychotic agents

is rather complex and many details remain to be established
(Swinyard, 1980).

Therefore, one might assume that altera

tion of water intake resulting from TRZ administration is
seldom anticipated. However, studies have shown that due to
alteration of water intake following administration of psy
chotropic agents (including TRZ), physiological changes
leading to behavioral disturbance can emerge.

Yet such

effects have been misinterpreted as manifestations of mental
illness

(Kosten and Camp, 1980; Miller, Moses, and Roao,

1975) rather than as conditions created by alteration of

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

27

water balance resulting from TRZ administration.
Shader and Dimascio (1970) have stated that a litera
ture review may give the impression that "behavioral side
effects" are relatively rare, and anticipated when they
occur.

They believe this to be a dangerous misconception,

largely attributable to an unclear definition of what con
stitutes "behavioral toxicity."

The literature review done

during preparation of the present thesis corroborates this
conclusion and apprehension.

If more frequent allusions to

behavioral side effects existed in the literature, a more
cautious approach to the use of psychotropic drugs might be
found which took into account both chemical structure and
mechanism of action.

Careful consideration of those popula

tions which receive combination TRZ-DPH treatment suggests
the disturbing possibility that deleterious drug-drug in
teraction effects may generally be masked and therefore go
undetected.
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APPENDIX
PHARMACOLOGY

Toxicity

Drug toxicity refers to pharmacological properties of
drugs that are harmful to an organism or that are so adverse
that therapeutic action of the drug in question is greatly
limited

(Plaa, 1972).

Zbinden (1963) has classified toxic

reactions into three categories of changes: functional,
biochemical, and structural.

Functional changes effect:

(1) behavior, leading to aggressiveness, agitation, anxiety,
depression, insomnia, psychosis, sedation, weakness, etc.;
(2) central and peripheral nervous system changes (i.e.,
convulsions, ataxia, extrapyramidal reactions); (3) sensory
organ changes (i.e. blurred vision);
respiratory system;

(4) cardiovascular and

(5) gastrointestinal system (i.e. con

stipation, nausea, porotid pain, etc.);

(6) urinary system;

and (7) akin (i.e., perspiration, etc.).

In regard to the

second classification, Zbinden refers to biochemical
toxicity as "reactions that do not produce gross evidence of
organ damage but which do cause changes in biochemical
reactions associated with various organs."

This could mani

fest itself in shifting hormonal balance, changes in acidbase balance, serum electrolytes, etc.

Structural changes

28
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refer to actual changes In the structure of the organ or
tissue involved.

(Plaa, 1972).

It is assumed that toxic effects of drugs can be
predicted and that such effects usually occur shortly after
administration of the drug

(Klasaen, 1980).

layed toxicity is not uncommon

(Plaa, 1972).

However, de
In deter

mining toxicity, the evaluation of dose-response or doseeffect is crucial.

The underlying principle behind this

concept is that for all chemicals and all biologic systems,
a dose can be found which will exert a maximum response and
one which exerts a minimum response, whereby the range of
response can be found between the maximum and the minimum.
The spectrum of undesirable side effects of drugs is rather
broad (Klasaen, 1980).

These involve:

(1) allergic reac

tions resulting from previous sensitization to a particular
chemical;

(2) idiosyncratic reactions, defined as abnormal

reactions to a chemical;

(3) delayed toxicity due to chronic

exposure to the drug; and (4) reversible and irreversible
toxic reactions.

Interaction

Whenever two or more drugs are given concommitantly,
the possibility of interaction exists
sar, 1980; Hicks, et al., 1980).
alteration of:

(Vincent, 1980; Hus

This often occurs via

(1) solubility and absorption of drugs; (2)
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metabolism or biot.ranaformat.ion; (3) renal excretion and
alteration of electrolyte balance
al., 1972; Hicks, et al., 1980).

(Goth, 1978; Kutt, et
Furthermore, the drugs

may compete for protein binding sites in plasma, and as such
constitute alterations of distribution

(Hicks, Funkenstein,

et al., 1980; Goth, 1980), resulting in large free-drug
concentrations in plasma, which can lead to undesirable side
effects and toxicity

(Glazko and Chung, 1972).

Inhibition

of metabolism often leads to elevation of drug plasma levels
and eventual toxicity as well
al., 1980; Klassen, 1980).

(Hussar, 1980; Hick3, et

Simultaneous administration of

DPH and other drugs often leads to alteration of DPH plasma
levels.

Drugs such as warfarin, disulfiram, phenylbutzone,

sulfaphanozole, and isoniazid may inhibit metabolism of DPH,
thus increasing serum level of it

(Swinyard, 1980; Eadie

and Tyrer, 1974; Kutt, et a l ., 1970).

High levels of free

fatty acid, solicilic acid, and butozolidine apparently
compete for protein binding sites, displacing quantities of
DPH from binding sites and into free plasma
Tyrer, 1974).

(Eadie and

The symptoms of DPH intoxication which can

then result are: dizziness, blurred vision, diplopia
(double-vision), nystagmus (involuntary rapid eye movement),
headache, irritability, feeling "drunk," unsteadiness,
ataxia (difficulty in muscle coordination), and drowsiness
(Kutt, et al., 1972).
The effects of concommitant use of psychotropic agents
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and anticonvulsants have been occasionally reported
Siris, et al., 1974; Gay and Madison, 1983).

<e.g.

A study by

Kutt <1972) indicates that when given simultaneously, chlorpromazine elevates DPH plasma levels and produces clinical
intoxication

(Kutt, et al., 1972).

Similar observations

have been made when TRZ and DPH are given concommitantly.
The case study reporting intoxication of two patients was
mentioned earlier

(Vincent, 1980).

However, in a study of

four patients conducted by Siris, Pippenger, Warner, and
Masland (1974) possible decrease in DPH levels, as a func
tion of TRZ treatment, is suggested.

Linnoila, et al.

(1980) have found no effect on plasma TRZ levels by concom
mitant use of anticonvulsant agents. In order to fully
evaluate the effects of this suspected interaction more
controlled studies are needed.

Phenytoin

Phenytoin (Diphenylhydantoin, Dilantin, DPH) was first
tested as a possible hypnotic.

Its anticonvulsant proper

ties were discovered by Merrit and Putnam (1938), and

has

since been used as the drug of choice for management of
various epileptic disorders (Chinitz, Seelinger, and Green
house, 1966; Tollefson, 1980), as well aa CNS and sensory
diseases of various ethiologies (Roth and Scheifer, 1980;
Livingston, 1966).

Moreover, DPH has been used for treat
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ment of mood, thought, and behavioral disorders.

(Davis, et

a l ., 1981; Eadie and Tyrer, 1974; Stephens and Shafner,
1973).
DPH is a white, crystalline, bitter-tasting powder.

It

is a lipid-soluble, weak acid, and is orally administered,
with intravenous and intramuscular administrations possible
(Swinyard, 1980).

DPH absorption rates depend upon numerous

factors such as site of administration, lipid solubility at
that site, pH level at the site, and drug concentration
(Woodbury and Swinyard, 1972).

DPH is distributed through

out body fluid and tissues, with highest concentrations in
liver, salivary glands, and kidney, and lower concentrations
in fat, muscle, and brain.

(Eadie and Tyrer, 1974).

Pheny

toin is biotransformed in liver, where metabolites are sub
sequently reabsorbed.

After entering the blood, DPH is

rapidly bound to plasma proteins

(Roth and Scheifer, 1980;

Tollefson, 1980). The biological half-life of phenytoin
(defined as the time that it takes for the concentration of
the drug to decline by 50«), averages about 22 hours with a
range of 7.0 to 42 hours
and Swinyard, 1972).

(Eadie and Tyrer, 1974; Woodbury

Phenytoin is excreted mainly through

urine, yet some is also eliminated via bile and feces

(Ea

die and Tyrer, 1974).
The adverse side effects of DPH are related to the
dosage of the drug, individual characteristics of the
patient, and the influence of other drugs

(Glaser, 1972).
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CNS effects due to DPH toxicity manifest themselves in
nystagmus, ataxia, ha>>»d tremor, double-vision, nausea, and
vomiting

(Eadie and Tyrer, 1974; Glaser, 1972).

Behavioral

effects include hyperactivity, confusion, inability to con
centrate, and lethargy
1982).

(Roth and Scheifer, 1980; Tollefson,

Furthermore, several cases of DPH encephalopathy

have been recognized by Glaser (1972) and Vallarta (1974).
DPH encephalopathy is characterized by increased seizure
frequency, EEG changes, alteration in mental function, im
paired intellectual function, "bizarre behavior," and exces
sive speech

(Reynolds and Travers, 1976).

Drug-induced

psychoses characterized by tactile and visual hallucination,
and "schizophrenic" reactions have also been documented
(Tollefson, 1982; Demers-Desrosiers, et al., 1970).

Other

adverse effects involve hypersensitivity reactions includ
ing, and associated with, fever, leukopenia (reduction of
the number of leukocytes in the blood), and lymphoadenophathy (disease of the lymph nodes)

(Choiken, Goldberg, and

Segel, 1958), gum hypertrophy (Livingston, 1966; Eadie and
Tyrer, 1974), gastrointestinal disturbances including nau
sea, and vomiting, and epigastric pain (Roth and Scheifer,
1980), hematological reactions including aplastic anemia,
agranylocytosis, and thrombocytophenia.
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Thioridazine

Phenothiazinea are among the moat widely uaed drugs in
medical practice (Baldesorini, 1980).

However, the full

mechanism of action of these agents has not yet been
adequately explained
Evaluation, 1983).

(Shader and Dimascio, 1970; AMA Drug
Detailed accounts of the pharmacokine

tics of phenothiazinea are often explained by using chlorpromazine as the protoype. The first phenothiazine (chlorpromazine) was synthesized and subsequently used in psychia
tric treatment in 1950; however, it has only been since the
mid-70's that chloropromazine and other phenothiazinea have
been uaed extensively as antipsychotic d^ugs

(Oakley; 1978,

Bernstein, 1978).
Thioridazine (Mellaril, TM Sandoz, Hannover NJ, TRZ) is
a white to slightly yellow granular powder, freely soluble
in water, chloroform, and methanol. It is an antipsychotic
agent whose pharmacological activity is similar to that of
other phenothiazinea; however, specific qualities such as
minimal antiemetic activity, decreased risk of hepatic dys
function, and minimal extrapyramidal stimulation make TRZ
distinct among the phenothiazinea
1981).

(Schmidt and Morgolin,

Thioridazine is primarily valued for its anxiety-

relieving effects

(Rech and Moore, 1971).

TRZ is used for the treatment of:

Consequently,

(1) moderate to marked

depression in adult patients (Bernstein, 1978); (2) multiple
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symptoms such as agitation anxiety, depressive mood tension,
fear, and senility in geriatric patients;

(3) several

behavioral problems in children, marked by combativeneaa
(e.g. explosive, hyperactive behavior, impulsivity, and
difficulty in sustaining attention)

(Gualtier, et al.,

1984; Polizos and Engelhardt, 1978);

<4) alleviation of a

wide range of schizophrenic symptoms and behaviors such as
thought disturbance, delusions, hallucination, and apathy
(Clark and Delguidice, 1970; Solomon and Patch, 1974).
TRZ is readily absorbed by the GI tract; however,
following oral administration (e.g. thioridazine is
administered orally only), absorption appears to be rather
erratic and unpredictable.

TRZ is distributed throughout

body fluid and tissues with highest concentrations in brain,
lungs, liver, kidneys, and spleen

(Baldesorini, 1980).

The

exact metabolic process of this agent has not been clearly
outlined, but principally, TRZ is metabolized in the liver
(Schmidt and Morgolin, 1981).

After entering the blood, TRZ

is rapidly bound 90 to 99 percent to plasma proteins
desorini, 1980).

(Bal

The biological half-life of TRZ appears to

be multiphasic with an early phase of 4 to 10 hours and a
late phase of 26 to 36 hours.

TRZ and its metabolites are

excreted in the urine but its complete excretory pattern has
not been characterized.

(Schmidt and Morgolin, 1981).

Specific side effects regarding thioridazine include:
(1)

adverse cholinergic effects such as dry mouth, blurred
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vision, and pallor

(Johnston, et al., 1980);

(2)

pyramidal symptoms including pseudoparkinsonism

extra(Gualtier,

et al., 1984; Polizos and Engelhardt, 1978); and (3)
dystonic reactions such as abrupt spasms of the head, neck,
and upper back muscles, and muscle spasms in the face,
throat, and tongue, these symptoms often being misinter
preted as seizures

(Ferguson and Ereuning, 1982);

(4)

CNS

effects such as drowsiness, nocturnal confusion, hyperac
tivity, lethargy, restlessness, and headache
Morgolin, 1981); (5)

(Schmidt and

cardiovascular effects such as postural

hypotension (considered the most troublesome side effect of
TRZ), EKG changes, and tachycardia (Moore and Rainey, 1982;
Gould, et al., 1984); (6)

gastrointestinal effects such as

constipation, nausea, vomiting, and diarrhea

(Shader and

Dimascio, 1970; Bernstein, 1978; Remmen, et al., 1962); (7)
endocrine effects such as enlargements of the breasts, amen
orrhea, inhibition of ejaculation, and peripheral edema
(Brambilla, et al., 1975; Kotin, et al., 1976); (8)

skin

and sensitivity reactions such as dermatitis, urticarial
skin eruptions, and photosensitivity;
plications

(9)

hematologic com

(Baldwin and Peters, 1968).

Numerous studies conducted on human and animal subjects
have indicated that there is marked alteration of learning
and performance due to antipsychotic drug treatment.
Breuning (1983), as well as Wysocki, Fuqua, and Davis (1981)
support this assumption.

Plotkln and Gill (1981) have
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argued that, the adaptive ability of the mentally retarded to
learn should be of special concern, for the ability of the
mentally retarded individual to learn is already limited due
to existing pathologies.
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